Navigation Links
Stason Pharmaceuticals Inc. announces Kansas City expansion, adds human health capabilities

KANSAS CITY, Kan., Nov. 8, 2013 /PRNewswire/ -- Stason Pharmaceuticals, Inc. announced today that it is expanding into Kansas City by moving its brand division from Irvine, Calif. to Kansas City, Kan.  A new entity has been developed, KC Specialty Therapeutics LLC, in which the new assets will be placed to focus on research and development of new chemical entities for humans.

"Stason Pharmaceuticals has been very impressed with the biosciences opportunities in the Kansas City region since moving Stason Animal Health's national headquarters here earlier this year," said Diana Wood, vice president of corporate development for Stason Pharmaceuticals and CEO for KC Specialty Therapeutics LLC. "The KC Animal Health Corridor and broader life sciences community have been incredibly supportive."

Today's announcement comes just 90 days after Stason Pharmaceutical's animal division, Stason Animal Health, announced it was relocating its corporate headquarters to the KC Animal Health Corridor.

KC Specialty Therapeutics LLC will locate alongside Stason Animal Health at the Bioscience & Technology Business Center located on the University of Kansas Medical Center campus.  Over the next year, the company will create job opportunities in Kansas City and continue to grow its presence over time.

"We are thrilled that Stason Pharmaceuticals values our region's strong biosciences business environment," said Bob Marcusse, president and CEO, Kansas City Area Development Council. "We look forward to seeing both Stason Pharmaceuticals and KC Specialty Therapeutics grow in our region."

About Stason Pharmaceuticals
Stason Pharmaceuticals entered the commercial generic market in 1994 and today continues to manufacture and market these products through a global network of distributors. Stason entered the contract manufacturing arena in 2000 to provide manufacturing support to other pharmaceutical companies, and in 2008, Stason launched its Brand Division. Headquartered in Southern California, the Stason group employs approximately 120 people worldwide.

About KC Specialty Therapeutics LLC
KC Specialty Pharma is focused on the development of new chemical entities in human orphan drug indications for which there is no available treatment.  Orphan drugs are defined as those that treat less than 200,000 in the US. 

About Greater Kansas City
Home to 2.5 million people, the Kansas City region offers the benefits of more than 50 unique communities and 18 counties in Kansas and Missouri.

SOURCE Kansas City Area Development Council
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Prodigy Health Supplier Partners with Stason Pharmaceuticals to Help Relieve U.S. Drug Shortages
2. Imprimis Pharmaceuticals, Inc. Announces Its Attendance at the American Academy of Ophthalmology in New Orleans, Nov. 16-19
3. ProVen Pharmaceuticals Participates in the Dolphins Cycling Challenge
4. Panacea Pharmaceuticals Presents Three Papers Regarding Its Nanoparticle-Based Therapeutic Cancer Vaccine at the Society for Immunotherapy of Cancer Annual Meeting at National Harbor, MD
5. Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2013 Financial Results
6. ANI Pharmaceuticals Reports Net Revenues of $7.8 million, adjusted Non-GAAP EBITDA of $1.7 Million, and EPS of $0.13 for the Third Quarter Ended September 30, 2013
7. Vanda Pharmaceuticals Reports Third Quarter 2013 Results
8. Questcor Pharmaceuticals to Present at the 2013 Credit Suisse Annual Healthcare Conference
9. Imprimis Pharmaceuticals Inc. Announces Shift in Strategic Direction
10. Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2013 Financial Results
11. Cadence Pharmaceuticals Reports Third Quarter 2013 Financial Results
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin ... companies that call for a minimum wage raise to $12 an hour by 2020 and ... This will restore the lost value of the minimum wage, assure the wage floor does ...
Breaking Medicine News(10 mins):